How has been the historical performance of Eiko Lifescience?

Answer:The historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, particularly from March 2018 to March 2025.

Breakdown:
Eiko Lifescience's net sales increased dramatically from 2.34 crore in March 2018 to 37.66 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 2.34 crore in March 2018 to 37.66 crore in March 2025. The company's total expenditure also grew, reaching 34.90 crore in March 2025, up from 1.99 crore in March 2018. Operating profit, which was 0.35 crore in March 2018, turned negative in subsequent years but rebounded to 3.48 crore by March 2025. Profit before tax showed a similar recovery, moving from 0.25 crore in March 2018 to 2.92 crore in March 2025. Consequently, profit after tax improved from 0.20 crore in March 2018 to 2.18 crore in March 2025, indicating a positive shift in the company's financial health. The consolidated net profit also turned positive, reaching 2.11 crore in March 2025 after being negative in previous years. The balance sheet reflects a substantial increase in shareholder's funds from 5.56 crore in March 2018 to 56.79 crore in March 2025, while total liabilities rose to 66.10 crore in March 2025, up from 10.95 crore in March 2018. Cash flow from operating activities improved significantly, resulting in a closing cash and cash equivalent of 11.00 crore in March 2025, compared to 0.00 crore in prior years. Overall, Eiko Lifescience has demonstrated a remarkable recovery and growth trajectory in its financial performance over the analyzed period.